Quest Diagnostics, Inc. DGX

NYS: DGX | ISIN: US74834L1008   24/12/2025
175,92 USD (+0,48%)
(+0,48%)   24/12/2025

19 december 2025 · Quest Diagnostics to Speak at the 44th Annual J.P. Morgan Healthcare Conference · Persbericht

11 november 2025 · Quest Diagnostics Declares Quarterly Cash Dividend · Persbericht

3 november 2025 · Quest Diagnostics to Speak at Citi's 2025 Global Healthcare Conference · Persbericht

27 oktober 2025 · New Study Demonstrates Accuracy of Two Quest AD-Detect® Tests for Alzheimer's Disease Diagnosis · Persbericht

21 oktober 2025 · Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025 · Persbericht

25 september 2025 · Quest Diagnostics to Release Third Quarter 2025 Financial Results on October 21, 2025 · Persbericht

23 september 2025 · Quest Diagnostics to Improve Laboratory Testing Experience with Industry-First Epic Collaboration · Persbericht

22 september 2025 · Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-Surgical Treatment for Lung Cancer · Persbericht

16 september 2025 · Quest Diagnostics to Speak at the Jefferies Healthcare Services Conference · Persbericht

4 september 2025 · Quest Diagnostics Launches Advanced Pharmacogenomics (PGx) Offering · Persbericht

2 september 2025 · Fentanyl Positivity Is More Than Seven Times Higher in Random Tests vs. Pre-Employment Drug Screening, Finds 2025 Quest Diagnostics Drug Testing Index · Persbericht

26 augustus 2025 · Corewell Health and Quest Diagnostics to Enter into Joint Venture Providing Enhanced Laboratory Services in Michigan · Persbericht

25 augustus 2025 · FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics · Persbericht

16 augustus 2025 · Quest Diagnostics to Speak at the Baird 2025 Global Healthcare Conference · Persbericht

14 augustus 2025 · Quest Diagnostics Declares Quarterly Cash Dividend · Persbericht

7 augustus 2025 · Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types · Persbericht

5 augustus 2025 · Quest Diagnostics Completes Acquisition of Clinical Testing Assets from Fresenius Medical Care · Persbericht

29 juli 2025 · Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene Sequencing · Persbericht

22 juli 2025 · Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025 · Persbericht

15 juli 2025 · Quest Diagnostics Introduces Testing for Oropouche Virus · Persbericht

Mijn selecties